flow trial semaglutide kidney outcomes 2024 nejm hazard ratio Original Article: Effects of on Chronic Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPte @ERAkidney Top Stories in Nephrology 2024
Description
For those comparing options, the semaglutide versus tirzepatide data shows similar weight regain patterns when either medication is discontinued
Essentially, Semaglutide helps you feel full longer while also controlling blood sugar levels, making it easier to shed pounds and sustain results
If successful, it may receive FDA approval by late 2025 or early 2026
The original research company is Novo Nordisk
